Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

DexCom, Inc.

DXCM

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

Last trade $82.17
Day change +$0.56 (+0.69%)
Day range $80.06 – $84.01
Volume 1,540,997
Market cap $30.44B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$30.44B
Price / earnings
30.71×
Price / book
12×
Price / sales
5.96×
EV / sales
6.02×
EV / EBITDA
20.5×

Profitability

Earnings per share
$2.66
Return on assets
15.88%
Return on equity
39.09%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.49×
Current ratio
1.74×
Quick ratio
1.4×
Cash ratio
0.43×

Cash flow

Price / cash flow
21.52×
Price / free cash flow
27.71×
Free cash flow
$1.1B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DXCM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.34B$1.31B$1.19B$1.26B$1.21B$1.16B$1.04B$1.11B
Cost of revenue$480.1M$478.4M$441.6M$466.9M$477.9M$468.3M$447M$457.7M
Gross profit$864.4M$830M$750.3M$792.7M$731.4M$688.8M$589M$655.8M
Selling, general and administrative$375.6M$358.7M$349.7M$321.5M$331.4M$328M$310.1M$327.4M
Research and development$161.6M$153M$145.3M$148.2M$157.5M$148.2M$145.2M$139.5M
Total operating expenses$537.2M$511.7M$495M$469.7M$488.9M$476.2M$455.3M$466.9M
Operating income$327.2M$318.3M$255.3M$323M$242.5M$212.6M$133.7M$188.9M
Interest expense$0-$3M$0$0$0-$4.7M$0$0
Income before taxes$334.7M$317.5M$269.5M$340.7M$352.3M$241.1M$154.3M$211.3M
Income taxes$59.6M$68.4M$70M$73.4M$68.5M$61.3M$48.9M$59.6M
Net income$275.1M$249.1M$199.5M$267.3M$283.8M$179.8M$105.4M$151.7M
Net income attributable to common shareholders$275.1M$249.1M$199.5M$267.3M$283.8M$179.8M$105.4M$151.7M
EBITDA$401.7M$386.5M$322.4M$388.2M$306.1M$275.6M$193.7M$246.7M
Basic earnings per share$0.73$0.65$0.52$0.69$0.73$0.46$0.27$0.39
Diluted earnings per share$0.72$0.64$0.51$0.67$0.70$0.45$0.27$0.37

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DexCom is well-positioned for growth driven by G7 15 Day adoption, international expansion, and manufacturing efficiencies that expanded Q3 gross margins to 65.1%. However, the company faces headwinds from PBM formulary risks, Ireland facility ramp-up costs, and rising R&D spending on G8 development. The stock has gained 22.6% year-to-date and maintains a Zacks Rank #3 (Hold) rating with improving 2026 earnings estimates.

Zacks Investment Research

DexCom to Launch 15-Day G7 CGM System in Canada This November

DexCom announced the November launch of its G7 15 Day Continuous Glucose Monitoring system in Canada, offering up to 15.5 days of sensor wear with 8.0% MARD accuracy. The system features waterproof sensors, Apple Watch connectivity, and will be supported by public and private reimbursement coverage. DXCM stock gained 7.8% following the announcement and has risen 27.7% year-to-date.

GlobeNewswire Inc.

Continuous Glucose Monitoring Market in India: USD 452.9 Million Opportunity by 2032 as Digital Diabetes Care Expands, Reports Mordor Intelligence

India's continuous glucose monitoring market is projected to grow at a CAGR of 11.90% from 2027-2032, reaching USD 452.9 million by 2032. The market expansion is driven by growing adoption of sensor-based monitoring, digital healthcare integration, and expanding diabetes management programs. However, high device costs and limited reimbursement coverage remain barriers to wider adoption.

Zacks Investment Research

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise

DexCom (DXCM) reported Q3 2026 adjusted EPS of 73 cents, beating estimates by 10.6%, with revenues growing 11.2% to $1.34B. U.S. revenues rose 13.8% while adjusted gross margin expanded 380 basis points to 65.1%. The company raised its 2026 revenue outlook to $5.20-$5.25B and authorized an additional $1B share buyback. International growth moderated to 4.8% due to prior-year reimbursement comparisons, but management expects recovery in early 2027.

Zacks Investment Research

DexCom Gears Up to Report Q3 Results: How to Play the Stock?

DexCom is expected to report Q3 2026 revenues of $1.32 billion (up 9.4% YoY) and EPS of 66 cents (up 8.2% YoY) on October 29. Growth is supported by G7 15 Day adoption, strong new-patient starts, and broader reimbursement coverage, though the company faces headwinds from tougher international comparisons, forex pressures, and manufacturing costs. An earnings beat is not predicted despite positive fundamentals.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 13, 20224-for-1forward split